Survival Curves

Sensitive vs. Resistant

Shown below are some survival curves comparing the survival of patients who tested sensitive to the agents they received, compared with those who were found resistant to the treatments that they received.

Breast Cancer

These results published in the Journal of Clinical Oncology reveal a statistically significant correlation between drug sensitivity and time to progression. This seminal paper reintroduced platinum-based chemotherapy for the treatment of advanced breast cancer. Related combinations continue to provide significant improvement in advanced breast cancer survival. Further reading

Ovarian Cancer

This analysis published in Gynecologic Oncology represents a prospective correlation between drug sensitivity to the combination of cisplatin and gemcitabine in patients with a mixture of platinum-sensitive and platinum-resistant disease. Results reveal a statistically significant correlation between drug sensitivity and time to progression.  In addition, this publication revealed a statistically significant correlation between drug sensitivity and clinical response, as well as drug sensitivity and overall survival.

This drug combination, developed by Rational Therapeutics, received FDA approval in July 2006 predicated upon this landmark study and the subsequent GOG clinical trial written by Dr. Nagourney (Gyn Oncol, 2006).

Further reading

Small Cell Lung Cancer

This analysis in small cell lung cancer, published by investigators at the National Cancer Institute, utilizing laboratory techniques developed and applied at Rational Therapeutics, correlates survival with the use of the “in vitro best regimen” (IVBR).

With a 39 percent durable complete remission rate for patients receiving assay “sensitive” therapy, this remains one of the best outcomes in this lethal disease ever reported.

Further reading


This analysis reveals a statistically significant survival advantage for patients receiving assay sensitive therapy in advanced metastatic melanoma. Despite melanoma’s drug refractory (resistant) nature, novel drug combinations provided durable responses in a high percentage of patients. Further reading

Chronic Lymphocytic Leukemia

CLL, the most common adult leukemia, is responsive to chemotherapy, but rarely curable. This analysis identifies a subset of patients with resistant disease who suffer early relapse and death. By identifying these patients at initial diagnosis, more effective therapies could be administered to provide more durable clinical response. Further reading

Lung Cancer Treatment Guide

by Robert A. Nagourney, MD
The incidence and mortality associated with advanced lung cancer represents one of the world’s greatest public health challenges. While progress in this disease has been disappointingly slow, there is renewed reason for hope. This guide outlines the current and future management options for this disease.

Published Papers

Papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death functional profiling assay, and effectiveness of new drugs and combinations.

Clinical Application of Assay-Directed Therapy

Predicted clinical outcomes for patients treated with agents found active in the laboratory using the EVA-PCD functional profile.

Physician Information

Find out how you can receive specific information on how your patient's cancer cells will react to single agents, combinations or targeted therapies.